Dr. Jonasch on Next Steps With MK-6482 in Von Hippel-Lindau Disease–Associated RCC
0 Views
administrator
07/02/23
Eric Jonasch, MD, discusses the next steps with the potent, selective, small molecule HIF-2α inhibitor MK-6482 in Von Hippel-Lindau disease–associated renal cell carcinoma.
Website: https://www.onclive.com
Twitter: https://twitter.com/OncLive
Facebook: https://www.facebook.com/OncLive/
LinkedIn: https://www.linkedin.com/company/onclive
-
Category
Show more
Facebook Comments
No comments found